New MS drug trial aims to quiet brain lesions
NCT ID NCT07321093
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapses better than an existing drug. About 292 adults aged 18-55 with RRMS will take part. The trial is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
LLC "Medis"
RECRUITINGNizhny Novgorod, Russia
Contact
Conditions
Explore the condition pages connected to this study.